share_log

Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target

Benzinga ·  May 8 11:40

Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment